A presentation on DNA Phenotyping Case Studies will be led by Dr. Steven Armentrout, Parabon’s President, during the 2018 Spring Seminar: Advances in DNA Technology, held in Atlantic City, New Jersey, May 11, 2018.
Reston, Va. (May 2018) – Parabon® NanoLabs, a vertically integrated DNA technology company that develops next-gen forensic and therapeutic products, will be presenting “Parabon Snapshot® DNA Phenotyping Case Studies” at the 2018 Spring Seminar: Advances in DNA Technology, to be held at The Tropicana in Atlantic City, New Jersey, May 11, 2018. The 2018 Spring Seminar is presented by the New Jersey Association of Forensic Scientists (NJAFS). The presentation will be led by Dr. Steven Armentrout, Parabon NanoLabs’ President.
Dr. Armentrout will discuss Snapshot, a revolutionary new forensic DNA analysis service that accurately predicts the physical appearance and ancestry of an unknown person from DNA. It can also determine kinship between DNA samples out to six degrees of relatedness. He will discuss how the service can aid in generating investigative leads, narrowing suspect lists and identifying unknown remains, and review actual cases where Snapshot has provided useful information to investigators.
The NJAFS is dedicated to the furtherance of the forensic sciences in the state of New Jersey. Its membership consists of practicing forensic scientists, academics, students and associates from numerous different institutions from around the state, as well as from other states within adjoining regions. NJAFS’ primary goal is to bring people together and foster communication between forensic scientists and their laboratories.
About Parabon® NanoLabs, Inc.:
Parabon® NanoLabs is a vertically integrated DNA technology company that develops next-generation forensic and therapeutic products, which leverage the enormous power of DNA. Staffed by a uniquely qualified team of scientists and technologists, with expertise ranging from bioinformatics and oncology to chemistry and computer science, the Company is bringing to market revolutionary new products and services made possible by recent advances in DNA sequencing, processing and manufacturing technologies.
